Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
- Record quarterly and full-year net revenue of $149.7 million and $566.8 million.
- Achieved quarterly and full-year GAAP net income of $31.9 million and $48.2 million.
- Delivered record quarterly and full-year adjusted EBITDA of $104.2 million and $367.0 million.
- Ended 2023 with cash, cash equivalents, and marketable securities of $310.5 million.
- Business highlights include growth in Belbuca total prescriptions, Xtampza ER gross-to-net, and capital return to shareholders.
- Reaffirmed full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA.
- Significant increases in net revenue, GAAP net income, and adjusted EBITDA for the quarter and year ended December 31, 2023.
- None.
The financial performance of Collegium Pharmaceutical, as detailed in their recent earnings report, indicates a robust fiscal position. The reported 22% year-over-year increase in net product revenues, coupled with a 10% decrease in GAAP operating expenses, suggests effective cost management and revenue growth. The substantial 38% increase in Adjusted EBITDA for the fiscal year further underscores operational efficiency and profitability. These results are likely to be well-received by investors, as they reflect both strong top-line growth and bottom-line improvement.
It is noteworthy that the company has also been actively managing its capital structure, paying down a significant portion of debt and engaging in share repurchase programs. Such activities can be accretive to earnings per share and are often viewed positively as they can indicate confidence by management in the company's future prospects. Additionally, the company's liquidity position, with over $300 million in cash and equivalents, provides flexibility for future investments or further shareholder returns.
Collegium's strategic focus on growing its key products, Belbuca and Xtampza ER, is reflected in their prescription growth and the renegotiation of Xtampza ER contracts. The pharmaceutical market, particularly in pain management where these products operate, is highly competitive and subject to regulatory and market pressures. Collegium's ability to navigate these challenges and deliver growth is indicative of strong market positioning and effective sales strategies.
Furthermore, the announcement of the U.S. Court of Appeals decision invalidating a competitor's patent suggests a favorable competitive landscape for Collegium's Xtampza ER. This could have implications for market share and pricing power, potentially bolstering future revenue streams. The submission of a pediatric extension to the FDA for the Nucynta Franchise may also extend market exclusivity, providing an additional strategic advantage and potentially enhancing long-term value.
The legal developments mentioned, such as the patent litigation outcome, are significant for Collegium Pharmaceutical. Patent disputes are common in the pharmaceutical industry and can have material impacts on a company's ability to market its products without competition. The court's decision to invalidate a competitor's patent claim over Xtampza ER removes a potential barrier to market access and may deter future litigation, reducing legal risks and associated costs.
In addition, the submission for a pediatric extension for the Nucynta Franchise could extend the product's market exclusivity, which is a critical component of a pharmaceutical company's intellectual property strategy. Such extensions can provide a temporary monopoly, allowing the company to maximize its revenue potential before facing generic competition. The outcome of this submission will be an important factor to monitor, as it could materially affect Collegium's future revenue and strategic planning.
– Generated Record Quarterly and Full-Year Net Revenue of
– Achieved Quarterly and Full-Year GAAP Net Income of
– Delivered Record Quarterly and Full-Year Adjusted EBITDA of
– Ended 2023 with Cash, Cash Equivalents and Marketable Securities of
– Conference Call Scheduled for Today at 4:30 p.m. ET –
STOUGHTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today reported its financial results for the quarter and full-year ended December 31, 2023, and provided a corporate update.
“2023 was a banner year for Collegium Pharmaceutical. We delivered record financial results, achieved our operational objectives and delivered value to shareholders through our share repurchase program,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Our focus in 2024 is on operational execution. We are committed to achieving our financial guidance and deploying capital to create value for our shareholders.”
“In 2023, we achieved our financial guidance, delivering record revenue, adjusted EBITDA and free cash flow. We strengthened our balance sheet by paying down
Business Highlights
- Grew Belbuca total prescriptions
3.2% in the quarter ended December 31, 2023, compared to the prior year quarter. - Recognized Xtampza ER gross-to-net of
59.6% for the full year 2023. - To date, returned
$137.0 million in capital to shareholders at an average price per share of$21.65 . In 2023, returned$75.0 million in capital to shareholders through accelerated share repurchase programs, including$25.0 million repurchased at an average price per share of$27.09 in the quarter ended December 31, 2023. - Completed Xtampza ER contract renegotiations; Xtampza ER gross-to-net is expected to be in the range of
56% to58% in 2024. - Announced the U.S. Court of Appeals decision upholding the judgment of the Patent Trial and Appeal Board in its final decision that Purdue’s ’961 patent, which Purdue has claimed is infringed by Xtampza ER, is invalid.
- Submitted a pediatric extension to the U.S. Food and Drug Administration (FDA) in December 2023 for the Nucynta Franchise to potentially extend exclusivity of the Nucynta Franchise an additional six months to December 27, 2025, for Nucynta® ER and January 3, 2027, for Nucynta®. The Company expects a decision in the second half of 2024.
- Authorized a new share repurchase program in January 2024 to repurchase up to
$150.0 million in common stock through the second quarter of 2025.
Financial Guidance for 2024
- The Company reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA:
| Product Revenues, Net | |
| Adjusted Operating Expenses (Excluding Stock-Based Compensation) | |
| Adjusted EBITDA (Excluding Stock-Based Compensation) |
Financial Results for Quarter Ended December 31, 2023
- Product revenues, net were
$149.7 million for the quarter ended December 31, 2023 (the 2023 Quarter), compared to$129.6 million for the quarter ended December 31, 2022 (the 2022 Quarter), representing a16% increase year-over-year. - GAAP operating expenses were
$32.9 million for the 2023 Quarter, compared to$38.0 million for the 2022 Quarter, representing a13% decrease year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were$25.9 million for the 2023 Quarter, compared to$32.3 million for the 2022 Quarter, representing a20% decrease year-over-year. - GAAP net income for the 2023 Quarter was
$31.9 million , with$0.99 GAAP earnings per share (basic) and$0.82 GAAP earnings per share (diluted), compared to GAAP net loss for the 2022 Quarter of$7.2 million , with$0.21 GAAP loss per share (basic and diluted). Non-GAAP adjusted net income for the 2023 Quarter was$64.2 million , with$1.58 adjusted earnings per share, compared to non-GAAP adjusted net income for the 2022 Quarter of$42.2 million , with$1.09 adjusted earnings per share. - Adjusted EBITDA for the 2023 Quarter was
$104.2 million , compared to$76.4 million for the 2022 Quarter, representing a36% increase year-over-year. - The Company exited the 2023 Quarter with cash, cash equivalents and marketable securities of
$310.5 million , up from$304.6 million as of September 30, 2023.
Financial Results for Year Ended December 31, 2023
- Product revenues, net were
$566.8 million for the year ended December 31, 2023 (FY 2023), compared to$463.9 million for the year ended December 31, 2022 (FY 2022), representing a22% increase year-over-year. - GAAP operating expenses were
$159.2 million for FY 2023, compared to$176.2 million for FY 2022, representing a10% decrease year-over-year. Adjusted operating expenses, which exclude stock-based compensation expense and other adjustments to reflect changes that occur in our business but do not represent ongoing operations, were$123.6 million for FY 2023, compared to$122.0 million for FY 2022, representing a1% increase year-over-year. - GAAP net income for FY 2023 was
$48.2 million , with$1.43 GAAP earnings per share (basic) and$1.29 GAAP earnings per share (diluted), compared to GAAP net loss for FY 2022 of$25.0 million , with$0.74 GAAP loss per share (basic and diluted). Non-GAAP adjusted net income for FY 2023 was$223.3 million , with$5.47 adjusted earnings per share, compared to non-GAAP adjusted net income for FY 2022 of$152.7 million , with$3.96 adjusted earnings per share. - Adjusted EBITDA for FY 2023 was
$367.0 million , compared to$266.0 million for FY 2022, representing a38% increase year-over-year.
Conference Call Information
The Company will host a conference call and live audio webcast on Thursday, February 22, 2024, at 4:30 p.m. ET. To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Q4 2023 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Non-GAAP Financial Measures
To supplement our financial results presented on a GAAP basis, we have included information about certain non-GAAP financial measures. We believe the presentation of these non-GAAP financial measures, when viewed with our results under GAAP and the accompanying reconciliations, provide analysts, investors, lenders, and other third parties with insights into how we evaluate normal operational activities, including our ability to generate cash from operations, on a comparable year-over-year basis and manage our budgeting and forecasting. In addition, certain non-GAAP financial measures, primarily Adjusted EBITDA, are used to measure performance when determining components of annual compensation for substantially all non-sales force employees, including senior management.
In our quarterly and annual reports, earnings press releases and conference calls, we may discuss the following financial measures that are not calculated in accordance with GAAP, to supplement our consolidated financial statements presented on a GAAP basis.
Adjusted EBITDA
Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude interest expense, interest income, the benefit from or provision for income taxes, depreciation, amortization, stock-based compensation, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.
There are several limitations related to the use of adjusted EBITDA rather than net income or loss, which is the nearest GAAP equivalent, such as:
- adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
- we exclude stock-based compensation expense from adjusted EBITDA although: (i) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; and (ii) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;
- adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;
- adjusted EBITDA does not reflect the benefit from or provision for income taxes or the cash requirements to pay taxes;
- adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments;
- we exclude impairment expenses from adjusted EBITDA and, although these are non-cash expenses, the asset(s) being impaired may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;
- we exclude restructuring expenses from adjusted EBITDA. Restructuring expenses primarily include employee severance and contract termination costs that are not related to acquisitions. The amount and/or frequency of these restructuring expenses are not part of our underlying business;
- we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred;
- we exclude acquisition related expenses as the amount and/or frequency of these expenses are not part of our underlying business. Acquisition related expenses include transaction costs, which primarily consisted of financial advisory, banking, legal, and regulatory fees, and other consulting fees, incurred to complete the acquisition, employee-related expenses (severance cost and benefits) for terminated employees after the acquisition, and miscellaneous other acquisition related expenses incurred;
- we exclude recognition of the step-up basis in inventory from acquisitions (i.e., the adjustment to record inventory from historic cost to fair value at acquisition) as the adjustment does not reflect the ongoing expense associated with sale of our products as part of our underlying business; and
- we exclude losses on extinguishments of debt as these expenses are episodic in nature and do not directly correlate to the cost of operating our business on an ongoing basis.
Adjusted Operating Expenses
Adjusted operating expenses is a non-GAAP financial measure that represents GAAP operating expenses adjusted to exclude stock-based compensation expense, and other adjustments to reflect changes that occur in our business but do not represent ongoing operations.
Adjusted Net Income and Adjusted Earnings Per Share
Adjusted net income is a non-GAAP financial measure that represents GAAP net income or loss adjusted to exclude significant income and expense items that are non-cash or not indicative of ongoing operations, including consideration of the tax effect of the adjustments. Adjusted earnings per share is a non-GAAP financial measure that represents adjusted net income per share. Adjusted weighted-average shares - diluted is calculated in accordance with the treasury stock, if-converted, or contingently issuable accounting methods, depending on the nature of the security.
Reconciliations of adjusted EBITDA, adjusted operating expenses, adjusted net income, and adjusted earnings per share to the most directly comparable GAAP financial measures are included in this press release.
The Company has not provided a reconciliation of its full-year 2024 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements. These items are uncertain and depend on various factors that are outside of the Company’s control or cannot be reasonably predicted. While the Company is unable to address the probable significance of these items, they could have a material impact on GAAP net income and operating expenses for the guidance period. A reconciliation of adjusted EBITDA or adjusted operating expenses would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our full-year 2024 financial guidance, including projected product revenue, adjusted operating expenses and adjusted EBITDA, current and future market opportunities for our products and our assumptions related thereto, expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact:
Christopher James, M.D.
Vice President, Investor Relations
ir@collegiumpharma.com
Media Contact:
Marissa Samuels
Vice President, Corporate Communications
communications@collegiumpharma.com
| Collegium Pharmaceutical, Inc. Unaudited Selected Consolidated Balance Sheet Information (in thousands) | |||||||
| December 31, | December 31, | ||||||
| 2023 | 2022 | ||||||
| Cash and cash equivalents | $ | 238,947 | $ | 173,688 | |||
| Marketable securities | 71,601 | — | |||||
| Accounts receivable, net | 179,525 | 183,119 | |||||
| Inventory | 32,332 | 46,501 | |||||
| Prepaid expenses and other current assets | 15,195 | 16,681 | |||||
| Property and equipment, net | 15,983 | 19,521 | |||||
| Operating lease assets | 6,029 | 6,861 | |||||
| Intangible assets, net | 421,708 | 567,468 | |||||
| Restricted cash | 1,047 | 2,547 | |||||
| Deferred tax assets | 26,259 | 23,950 | |||||
| Other noncurrent assets | 825 | 100 | |||||
| Goodwill | 133,857 | 133,695 | |||||
| Total assets | $ | 1,143,308 | $ | 1,174,131 | |||
| Accounts payable and accrued liabilities | 46,263 | 39,623 | |||||
| Accrued rebates, returns and discounts | 227,331 | 230,491 | |||||
| Term notes payable | 405,046 | 560,078 | |||||
| Convertible senior notes | 262,125 | 140,873 | |||||
| Operating lease liabilities | 7,112 | 8,224 | |||||
| Shareholders’ equity | 195,431 | 194,842 | |||||
| Total liabilities and stockholders’ equity | $ | 1,143,308 | $ | 1,174,131 | |||
| Collegium Pharmaceutical, Inc. Unaudited Condensed Statements of Operations (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Product revenues, net | $ | 149,745 | $ | 129,620 | $ | 566,767 | $ | 463,933 | |||||||
| Cost of product revenues | |||||||||||||||
| Cost of product revenues (excluding intangible asset amortization) | 20,601 | 37,552 | 94,838 | 118,190 | |||||||||||
| Intangible asset amortization and impairment | 34,514 | 42,279 | 145,760 | 136,255 | |||||||||||
| Total cost of products revenues | 55,115 | 79,831 | 240,598 | 254,445 | |||||||||||
| Gross profit | 94,630 | 49,789 | 326,169 | 209,488 | |||||||||||
| Operating expenses | |||||||||||||||
| Research and development | — | — | — | 3,983 | |||||||||||
| Selling, general and administrative | 32,942 | 38,032 | 159,208 | 172,186 | |||||||||||
| Total operating expenses | 32,942 | 38,032 | 159,208 | 176,169 | |||||||||||
| Income from operations | 61,688 | 11,757 | 166,961 | 33,319 | |||||||||||
| Interest expense | (19,281 | ) | (20,575 | ) | (83,339 | ) | (63,213 | ) | |||||||
| Interest income | 4,303 | 1,027 | 15,615 | 1,047 | |||||||||||
| Loss on extinguishment of debt | — | — | (23,504 | ) | — | ||||||||||
| Income (loss) before income taxes | 46,710 | (7,791 | ) | 75,733 | (28,847 | ) | |||||||||
| Provision for (benefit from) income taxes | 14,770 | (592 | ) | 27,578 | (3,845 | ) | |||||||||
| Net income (loss) | $ | 31,940 | $ | (7,199 | ) | $ | 48,155 | $ | (25,002 | ) | |||||
| Earnings (loss) per share — basic | $ | 0.99 | $ | (0.21 | ) | $ | 1.43 | $ | (0.74 | ) | |||||
| Weighted-average shares — basic | 32,301,211 | 33,582,202 | 33,741,213 | 33,829,495 | |||||||||||
| Earnings (loss) per share — diluted | $ | 0.82 | $ | (0.21 | ) | $ | 1.29 | $ | (0.74 | ) | |||||
| Weighted-average shares — diluted | 41,279,981 | 33,582,202 | 41,788,125 | 33,829,495 | |||||||||||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands) (unaudited) | |||||||||||||||||||||
| Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||
| GAAP net income (loss) | $ | 31,940 | $ | (7,199 | ) | $ | 48,155 | $ | (25,002 | ) | |||||||||||
| Adjustments: | |||||||||||||||||||||
| Interest expense | 19,281 | 20,575 | 83,339 | 63,213 | |||||||||||||||||
| Interest income | (4,303 | ) | (1,027 | ) | (15,615 | ) | (1,047 | ) | |||||||||||||
| Loss on extinguishment of debt | — | — | 23,504 | — | |||||||||||||||||
| Provision for (benefit from) income taxes | 14,770 | (592 | ) | 27,578 | (3,845 | ) | |||||||||||||||
| Depreciation | 949 | 825 | 3,496 | 2,684 | |||||||||||||||||
| Amortization | 34,514 | 37,493 | 145,760 | 131,469 | |||||||||||||||||
| Impairment expense | — | 4,786 | — | 4,786 | |||||||||||||||||
| Stock-based compensation | 7,002 | 5,670 | 27,136 | 22,874 | |||||||||||||||||
| Litigation settlements | — | — | 8,500 | — | |||||||||||||||||
| Acquisition related expenses | — | 88 | — | 31,297 | |||||||||||||||||
| Recognition of step-up basis in inventory | — | 15,824 | 15,116 | 39,584 | |||||||||||||||||
| Total adjustments | $ | 72,213 | $ | 83,642 | $ | 318,814 | $ | 291,015 | |||||||||||||
| Adjusted EBITDA | $ | 104,153 | $ | 76,443 | $ | 366,969 | $ | 266,013 | |||||||||||||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands) (unaudited) | |||||||||||||||
| Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP operating expenses | $ | 32,942 | $ | 38,032 | $ | 159,208 | $ | 176,169 | |||||||
| Adjustments: | |||||||||||||||
| Stock-based compensation | 7,002 | 5,670 | 27,136 | 22,874 | |||||||||||
| Litigation settlements | — | — | 8,500 | — | |||||||||||
| Acquisition related expenses | — | 88 | — | 31,297 | |||||||||||
| Total adjustments | $ | 7,002 | $ | 5,758 | $ | 35,636 | $ | 54,171 | |||||||
| Adjusted operating expenses | $ | 25,940 | $ | 32,274 | $ | 123,572 | $ | 121,998 | |||||||
| Collegium Pharmaceutical, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts) (unaudited) | |||||||||||||||
| Three Months Ended December 31, | Years Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP net income (loss) | $ | 31,940 | $ | (7,199 | ) | $ | 48,155 | $ | (25,002 | ) | |||||
| Adjustments: | |||||||||||||||
| Non-cash interest expense | 1,963 | 2,383 | 8,635 | 8,285 | |||||||||||
| Loss on extinguishment of debt | — | — | 23,504 | — | |||||||||||
| Amortization | 34,514 | 37,493 | 145,760 | 131,469 | |||||||||||
| Impairment expense | — | 4,786 | — | 4,786 | |||||||||||
| Stock-based compensation | 7,002 | 5,670 | 27,136 | 22,874 | |||||||||||
| Litigation settlements | — | — | 8,500 | — | |||||||||||
| Acquisition related expenses | — | 88 | — | 31,297 | |||||||||||
| Recognition of step-up basis in inventory | — | 15,824 | 15,116 | 39,584 | |||||||||||
| Income tax effect of above adjustments(1) | (11,252 | ) | (16,855 | ) | (53,526 | ) | (60,553 | ) | |||||||
| Total adjustments | $ | 32,227 | $ | 49,389 | $ | 175,125 | $ | 177,742 | |||||||
| Non-GAAP adjusted net income | $ | 64,167 | $ | 42,190 | $ | 223,280 | $ | 152,740 | |||||||
| Adjusted weighted-average shares — diluted(2) | 41,279,982 | 39,644,115 | 41,788,125 | 39,531,814 | |||||||||||
| Adjusted earnings per share(2) | $ | 1.58 | $ | 1.09 | $ | 5.47 | $ | 3.96 | |||||||
(1) The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax effect. The blended federal and state statutory rate for the three months ended December 31, 2023 and 2022 were
(2) Adjusted weighted-average shares - diluted were calculated using the “if-converted” method for the convertible notes in accordance with ASC 260, Earnings per Share. As such, adjusted weighted-average shares – diluted includes shares related to the assumed conversion of our convertible notes and the associated cash interest expense added-back to non-GAAP adjusted net income. For the three months ended December 31, 2023 and 2022, adjusted weighted-average shares – diluted includes 7,509,104 and 4,925,134 shares, respectively, attributable to our convertible notes. For the years ended December 31, 2023 and 2022, adjusted weighted-average shares – diluted includes 6,793,421 and 4,925,134 shares, respectively, attributable to our convertible notes. In addition, adjusted earnings per share includes other potentially dilutive securities to the extent that they are not antidilutive.
FAQ
What were Collegium Pharmaceutical's record quarterly and full-year net revenues?
What were the quarterly and full-year GAAP net incomes for Collegium Pharmaceutical?
What was Collegium Pharmaceutical's record quarterly and full-year adjusted EBITDA?
How much cash, cash equivalents, and marketable securities did Collegium Pharmaceutical end 2023 with?
What were the business highlights for Collegium Pharmaceutical?
What is Collegium Pharmaceutical's full-year 2024 guidance for product revenues, net, adjusted operating expenses, and adjusted EBITDA?
How did Collegium Pharmaceutical's financial results for the quarter and year ended December 31, 2023, compare to the previous year?
